Page 180 - 2022_03-Haematologica-web

Letters to the Editor
1Center for Oncology Hematology Outcomes Research and Training (COHORT), Division of Hematology and Oncology, University of California Comprehensive Cancer Center, Sacramento, CA; 2Center for Healthcare Policy and Research, University of California, Davis, School of Medicine, Sacramento, CA; 3Department of Oncology, Division of Hematology and Oncology, St. Jude Children’s Research Hospital, Memphis, TN and 4Department of Pediatrics, Division of Hematology and Oncology, University of California, Davis, School of Medicine, Sacramento, CA, USA
Correspondence:
RENATA ABRAHAO - rabrahao@ucdavis.edu doi:10.3324/haematol.2021.278851 Received: March 26, 2021.
Accepted: May 4, 2021.
Pre-published: July 29, 2021.
Disclosures: no conflicts of interest to disclose.
Contributions: RA and THMK conceived and designed the study; THMK and TW acquired data; RA analyzed data and drafted the manuscript. All authors reviewed and approved the final version of the manuscript.
Funding: RA was supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number T32HP30037 for Research in Primary Care. THMK was supported by the UC Davis Comprehensive Cancer Center (P30CA093373). TW was supported by UL1 0000860, National Center for Advancing Translational Science, National Institute of Health (NIH). RCR was partially funded by the National Cancer Institute (NCI) grant CA21765 and by the American Lebanese and Syrian Associated Charities. The collection
of cancer incidence data used in this study was supported by the California Department of Public Health pursuant to California Health and Safety Code Section 103885; Centers for Disease Control and Prevention’s (CDC) National Program of Cancer Registries, under cooperative agreement 5NU58DP006344; the NCI’s Surveillance, Epidemiology and End Results (SEER) Program under contract HHSN261201800032I awarded to the University of California, San Francisco, contract HHSN261201800015I awarded to the University of Southern California, and contract HHSN261201800009I awarded to the Public Health Institute. The ideas and opinions expressed herein are those of the authors and do not necessarily reflect the opinions of the State of California, Department of Public Health, the NCI, and the CDC or their Contractors and Subcontractors. Likewise, they should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the U.S. Government.
References
1. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113(9):1875- 1891.
2. Ho G, Li Q, Brunson A, et al. Complications and early mortality in patients with acute promyelocytic leukemia treated in California. Am J Hematol. 2018;93(11): E370-E372.
3. Lehmann S, Deneberg S, Antunovic P, et al. Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997-2013. Leukemia. 2017;31(6):1457-1459.
4.Abrahao R, Ribeiro RC, Medeiros BC, et al. Disparities in early death and survival in children, adolescents, and young adults with acute promyelocytic leukemia in California. Cancer. 2015; 121(22):3990-3997.
5. Yost K, Perkins C, Cohen R, et al. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control. 2001;12(8):703-711.
6. Abla O, Lo-Coco F, Sanz MA. Acute Promyelocytic Leukemia. First edition: Springer International Publishing (Chapter 6). 2018.
7. Lo-Coco F, Cicconi L, Voso MT. Progress and criticalities in the man- agement of acute promyelocytic leukemia. Oncotarget. 2017; 8(59): 99221-99222.
8. Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(13):1295-1305.
9. Kirchhoff AC, Lyles CR, Fluchel M, et al. Limitations in health care access and utilization among long-term survivors of adolescent and young adult cancer. Cancer. 2012;118(23):5964-5972.
10. Zhao J, Mao Z, Fedewa SA, et al. The Affordable Care Act and access to care across the cancer control continuum: a review at 10 years. CA Cancer J Clin. 2020;70(3):165-181.
11. Giri S, Pathak R, Aryal MR, et al. Impact of hospital volume on out- comes of patients undergoing chemotherapy for acute myeloid leukemia: a matched cohort study. Blood. 2015;125(21):3359-3360.
12. Lo-Coco F, Di Donato L, Schlenk RF. Targeted therapy alone for acute promyelocytic leukemia. N Engl J Med. 2016;374(12):1197- 1198.
13. Cicconi L, Platzbecker U, Avvisati G, et al. Long-term results of all- trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. Leukemia. 2020;34(3):914-918.
14. NAACCR Latino Research Work Group. NAACCR Guideline for Enhancing Hispanic-Latino Identification: Revised NAACCR Hispanic/Latino Identification Algorithm [NHIA v2]. Springfield (IL). North American Association of Central Cancer Registries, September 2005.
15. NAACCR Race and Ethnicity Work Group. NAACCR Asian Pacific Islander Identification Algorithm [NAPIIA v1.2.1]. Springfield (IL), August 2011.
736
haematologica | 2022; 107(3)